Global NewsNews

Lupin, Aurobindo units recall products in US market

The drug is used to relieve mild to moderate pain and reduce fever

US-based units of drug firms Lupin and Aurobindo Pharma are recalling certain products in the American market, as per the latest enforcement report of the US Food and Drug Administration (US FDA). Baltimore-based Lupin Pharmaceuticals Inc, an arm of the Mumbai-based drug maker, is recalling 46,479 bottles of anti-viral medication Oseltamivir Phosphate for Oral Suspension. 

THIS CAN BE YOUR ADVERTISEMENT

East Windsor-based AuroMedics Pharma, a unit of Hyderabad-based Aurobindo Pharma, is recalling 3,094 cartons of Acetaminophen injection. 

The drug is used to relieve mild to moderate pain and reduce fever. 

US FDA noted that Lupin has initiated the recall of the affected lot due to, “Failed Impurities/Degradation Specifications”. 

The product has been manufactured at Lupin’s Aurangabad (Maharashtra) based manufacturing plant. 

The company initiated the recall, which the US health regulator has classified as Class III, on January 21 this year. 

As per the US FDA, a class III recall is initiated in a “situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences”. 

AuroMedics Pharma is recalling affected lots of Acetaminophen injection which have been produced in India, US FDA said. 

The company is recalling the lot due to “discolouration and failed pH specifications”, it added. 

AuroMedics initiated the nationwide recall on December 30, 2020. 

The US FDA has classified the initiative as a Class II recall, which is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Leave a Reply

Back to top button
Close
Close